BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 23727861)

  • 1. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.
    Wang G; Lunardi A; Zhang J; Chen Z; Ala U; Webster KA; Tay Y; Gonzalez-Billalabeitia E; Egia A; Shaffer DR; Carver B; Liu XS; Taulli R; Kuo WP; Nardella C; Signoretti S; Cordon-Cardo C; Gerald WL; Pandolfi PP
    Nat Genet; 2013 Jul; 45(7):739-746. PubMed ID: 23727861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetics: ZBTB7A suppresses castration-resistant prostate cancer.
    Razzak M
    Nat Rev Clin Oncol; 2013 Aug; 10(8):427. PubMed ID: 23774644
    [No Abstract]   [Full Text] [Related]  

  • 3. ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer.
    Han D; Chen S; Han W; Gao S; Owiredu JN; Li M; Balk SP; He HH; Cai C
    Cancer Res; 2019 Oct; 79(20):5260-5271. PubMed ID: 31444154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.
    Manda KR; Tripathi P; Hsi AC; Ning J; Ruzinova MB; Liapis H; Bailey M; Zhang H; Maher CA; Humphrey PA; Andriole GL; Ding L; You Z; Chen F
    Oncogene; 2016 Jun; 35(25):3282-92. PubMed ID: 26477312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation.
    Thomsen MK; Ambroisine L; Wynn S; Cheah KS; Foster CS; Fisher G; Berney DM; Møller H; Reuter VE; Scardino P; Cuzick J; Ragavan N; Singh PB; Martin FL; Butler CM; Cooper CS; Swain A;
    Cancer Res; 2010 Feb; 70(3):979-87. PubMed ID: 20103652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
    Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
    Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
    Lunardi A; Varmeh S; Chen M; Taulli R; Guarnerio J; Ala U; Seitzer N; Ishikawa T; Carver BS; Hobbs RM; Quarantotti V; Ng C; Berger AH; Nardella C; Poliseno L; Montironi R; Castillo-Martin M; Cordon-Cardo C; Signoretti S; Pandolfi PP
    Cancer Discov; 2015 May; 5(5):550-63. PubMed ID: 25653093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer: of mice and men--a co-clinical approach to CRPC.
    Payton S
    Nat Rev Urol; 2013 Aug; 10(8):429. PubMed ID: 23774961
    [No Abstract]   [Full Text] [Related]  

  • 9. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.
    Alimonti A; Nardella C; Chen Z; Clohessy JG; Carracedo A; Trotman LC; Cheng K; Varmeh S; Kozma SC; Thomas G; Rosivatz E; Woscholski R; Cognetti F; Scher HI; Pandolfi PP
    J Clin Invest; 2010 Mar; 120(3):681-93. PubMed ID: 20197621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leveraging the species barrier to advance cancer therapy.
    Zhao S; Nelson PS
    Nat Genet; 2013 Jul; 45(7):718-20. PubMed ID: 23800864
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Parisotto M; Grelet E; El Bizri R; Dai Y; Terzic J; Eckert D; Gargowitsch L; Bornert JM; Metzger D
    J Exp Med; 2018 Jun; 215(6):1749-1763. PubMed ID: 29743291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression.
    Redmer T; Raigel M; Sternberg C; Ziegler R; Probst C; Lindner D; Aufinger A; Limberger T; Trachtova K; Kodajova P; Högler S; Schlederer M; Stoiber S; Oberhuber M; Bolis M; Neubauer HA; Miranda S; Tomberger M; Harbusch NS; Garces de Los Fayos Alonso I; Sternberg F; Moriggl R; Theurillat JP; Tichy B; Bystry V; Persson JL; Mathas S; Aberger F; Strobl B; Pospisilova S; Merkel O; Egger G; Lagger S; Kenner L
    Mol Cancer; 2024 May; 23(1):114. PubMed ID: 38811984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers.
    Burdelski C; Bujupi E; Tsourlakis MC; Hube-Magg C; Kluth M; Melling N; Lebok P; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Simon R; Schlomm T; Steurer S; Krech T
    PLoS One; 2015; 10(6):e0128525. PubMed ID: 26030748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of JUNB/AP-1 promotes invasive prostate cancer.
    Thomsen MK; Bakiri L; Hasenfuss SC; Wu H; Morente M; Wagner EF
    Cell Death Differ; 2015 Apr; 22(4):574-82. PubMed ID: 25526087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZBTB7A suppresses glioblastoma tumorigenesis through the transcriptional repression of EPB41L5.
    Jeong JH; Park SH; Kim H; Nam HY; Kim SH; Jeong M; Kong MJ; Son J; Jeong JE; Song JH; Kim SW; Choi KC
    Exp Mol Med; 2023 Jan; 55(1):43-54. PubMed ID: 36596853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
    Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
    Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.
    Cai C; Wang H; He HH; Chen S; He L; Ma F; Mucci L; Wang Q; Fiore C; Sowalsky AG; Loda M; Liu XS; Brown M; Balk SP; Yuan X
    J Clin Invest; 2013 Mar; 123(3):1109-22. PubMed ID: 23426182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
    Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
    Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LZTS2 and PTEN collaboratively regulate ß-catenin in prostatic tumorigenesis.
    Yu EJ; Hooker E; Johnson DT; Kwak MK; Zou K; Luong R; He Y; Sun Z
    PLoS One; 2017; 12(3):e0174357. PubMed ID: 28323888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging role of ZBTB7A as an oncogenic driver and transcriptional repressor.
    Gupta S; Singh AK; Prajapati KS; Kushwaha PP; Shuaib M; Kumar S
    Cancer Lett; 2020 Jul; 483():22-34. PubMed ID: 32348807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.